Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Laurent GarderetGösta Gahrton

Abstract

This prospective multicenter phase III study compared the efficacy and safety of a triple combination (bortezomib-thalidomide-dexamethasone [VTD]) versus a dual combination (thalidomide-dexamethasone [TD]) in patients with multiple myeloma (MM) progressing or relapsing after autologous stem-cell transplantation (ASCT). Overall, 269 patients were randomly assigned to receive bortezomib (1.3 mg/m(2) intravenous bolus) or no bortezomib for 1 year, in combination with thalidomide (200 mg per day orally) and dexamethasone (40 mg orally once a day on 4 days once every 3 weeks). Bortezomib was administered on days 1, 4, 8, and 11 with a 10-day rest period (day 12 to day 21) for eight cycles (6 months), and then on days 1, 8, 15, and 22 with a 20-day rest period (day 23 to day 42) for four cycles (6 months). Median time to progression (primary end point) was significantly longer with VTD than TD (19.5 v13.8 months; hazard ratio, 0.59; 95% CI, 0.44 to 0.80; P = .001), the complete response plus near-complete response rate was higher (45% v 21%; P 0.001), and the median duration of response was longer (17.9 v 13.4 months; P.04) [corrected].The 24-month survival rate was in favor of VTD (71% v 65%; P = .093). Grade 3 peripheral neuropathy...Continue Reading

References

Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Jun 17, 2005·The New England Journal of Medicine·Paul G RichardsonUNKNOWN Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators
Mar 10, 2006·The New England Journal of Medicine·Bart BarlogieJohn Crowley
Jul 29, 2006·Blood·Michel AttalUNKNOWN Inter-Groupe Francophone du Myélome (IFM)
Sep 19, 2006·European Journal of Haematology·M Teresa CibeiraJoan Bladé
Sep 22, 2006·Current Opinion in Oncology·Paul G RichardsonKenneth Anderson
Aug 8, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert Z OrlowskiJean-Luc Harousseau
Nov 23, 2007·The New England Journal of Medicine·Meletios DimopoulosUNKNOWN Multiple Myeloma (010) Study Investigators
Nov 23, 2007·The New England Journal of Medicine·Donna M WeberUNKNOWN Multiple Myeloma (009) Study Investigators
Mar 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew SpencerNola Kennedy
Apr 25, 2009·Seminars in Hematology·Efstathios KastritisMeletios A Dimopoulos
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marco LadettoAntonio Palumbo
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Asher A Chanan-Khan, Sergio Giralt
Jan 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David C JohnsonGareth J Morgan

❮ Previous
Next ❯

Citations

Nov 19, 2013·Annals of Hematology·Silvia ParkKihyun Kim
Oct 23, 2013·Current Hematologic Malignancy Reports·Sergio Giralt, Guenther Koehne
Dec 11, 2013·Clinical Oncology : a Journal of the Royal College of Radiologists·C T KouroukisM C Cheung
Aug 21, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P MoreauUNKNOWN ESMO Guidelines Working Group
Jun 27, 2014·BioMed Research International·Alessandra RomanoFrancesco Di Raimondo
Jul 30, 2014·Archives of Toxicology·Andreas A ArgyriouHaralabos P Kalofonos
Mar 14, 2013·Blood·Gösta GahrtonUNKNOWN EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee
Mar 16, 2013·Leukemia & Lymphoma·Morie A Gertz, Martha Q Lacy
Jan 30, 2014·Expert Review of Hematology·Jacob P LaubachPaul G Richardson
Dec 26, 2015·Clinical Lymphoma, Myeloma & Leukemia·Ryan W JacobsMuzaffar H Qazilbash
Oct 12, 2013·British Journal of Haematology·Djordje Atanackovic, Georgia Schilling
Mar 24, 2016·Annals of the New York Academy of Sciences·Heather FairfieldMichaela R Reagan
Apr 4, 2015·Future Oncology·Paul G RichardsonShaji Kumar
Feb 12, 2015·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Denise NiewerthJacqueline Cloos
Feb 14, 2015·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Ling PengQiong Zhao
Apr 4, 2015·Blood·Ajay K NookaSagar Lonial
Dec 9, 2014·The New England Journal of Medicine·A Keith StewartUNKNOWN ASPIRE Investigators
Oct 19, 2013·Blood·Sagar Lonial
Nov 26, 2014·Nature Reviews. Clinical Oncology·Meletios A DimopoulosKenneth C Anderson
Apr 28, 2016·The New England Journal of Medicine·Philippe MoreauUNKNOWN TOURMALINE-MM1 Study Group
May 19, 2016·Cancer·Ajay K Nooka, Sagar Lonial
Nov 13, 2007·Hematology/oncology Clinics of North America·Angela Dispenzieri
Sep 13, 2014·Hematology/oncology Clinics of North America·Silvia Gentili, Sagar Lonial
Dec 8, 2015·Hematology·Sagar Lonial, Ajay K Nooka

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.